000778009 000__ 03929cam\a2200469Mi\4500
000778009 001__ 778009
000778009 005__ 20230306142746.0
000778009 006__ m\\\\\o\\d\\\\\\\\
000778009 007__ cr\nn\nnnunnun
000778009 008__ 161119t20162017sz\\\\\\ob\\\\000\0\eng\d
000778009 020__ $$a9783319432960$$q(electronic book)
000778009 020__ $$a3319432966$$q(electronic book)
000778009 020__ $$z9783319432946
000778009 035__ $$aSP(OCoLC)ocn963696106
000778009 035__ $$aSP(OCoLC)963696106
000778009 040__ $$aEBLCP$$beng$$epn$$cEBLCP$$dN$T$$dIDEBK$$dGW5XE$$dOCLCQ$$dUAB$$dIOG
000778009 049__ $$aISEA
000778009 050_4 $$aRC662.18
000778009 050_4 $$aR1
000778009 08204 $$a616.4/62406$$223
000778009 08204 $$a610
000778009 1001_ $$aFisher, Miles.
000778009 24510 $$aEssentials of SGLT2 inhibitors in diabetes /$$cMiles Fisher, Gerard McKay.
000778009 260__ $$aCham :$$bAdis,$$c[2016], ©2017.
000778009 300__ $$a1 online resource (77 pages)
000778009 336__ $$atext$$btxt$$2rdacontent
000778009 337__ $$acomputer$$bc$$2rdamedia
000778009 338__ $$aonline resource$$bcr$$2rdacarrier
000778009 504__ $$aIncludes bibliographical references.
000778009 5050_ $$aBiographies; Contents; Editors; Contributors; Chapter 1: Overview ofßType 2 Diabetes; 1.1 Epidemiology andßGlobal Disease Burden; 1.2 Diagnostic Criteria forßDiabetes; 1.3 Glucose Homeostasis; 1.4 Pathogenesis ofßType 2 Diabetes; 1.5 Risk Factors forßtheßDevelopment ofßDiabetes; 1.6 Clinical Features ofßDiabetes; 1.7 Complications ofßDiabetes; References; Chapter 2: SGLT2 Inhibitors forßTreating Diabetes; 2.1 Mode ofßAction andßClinical Pharmacology; 2.2 Drug Development andßMajor Clinical Trials; 2.2.1 Phlorizin; 2.2.2 Glycemic Effects ofßDapagliflozin.
000778009 5058_ $$a2.2.3 Glycemic Effects ofßCanagliflozin2.2.4 Glycemic Effects ofßEmpagliflozin; 2.2.5 Glycemic Effects ofßSGLT2 Inhibitors: Where Are WeßNow?; 2.3 Effects ofßSGLT2 Inhibitors onßBody Weight; 2.4 Effects ofßSGLT Inhibitors onßBlood Pressure; 2.5 Adverse Effects andßSafety; 2.5.1 Hypoglycemia withßSGLT2 Inhibitors; 2.5.2 Genital Infections; 2.5.3 Volume Depletion; 2.5.4 Effects ofßSGLT2 Inhibitors onßLipids; 2.5.5 Effects onßRenal Function; 2.5.6 Fractures; 2.6 Ketoacidosis; References; Chapter 3: Guidelines forßtheßTreatment ofßType 2 Diabetes Mellitus; 3.1 Introduction.
000778009 5058_ $$a3.2 International Diabetes Federation Guidelines3.3 Joint American Diabetes Association andßEuropean Association forßtheßStudy ofßDiabetes Position Statement; 3.3.1 Update toßtheßJoint ADA/EASD Position Statement; 3.4 Country Case Study: Developing Guidelines inßtheßUK; 3.5 Conclusion; References; Chapter 4: Using SGLT2 Inhibitors inßSpecial Populations; 4.1 Introduction; 4.2 SGLT2 Inhibitors inßPatients withßCardiovascular Disease; 4.2.1 EMPA-REG OUTCOME; 4.2.2 Cardiovascular Trials withßOther SGLT2 Inhibitors; 4.3 SGLT2 Inhibitors inßPatients withßChronic Kidney Disease.
000778009 5058_ $$a4.3.1 Cohort Analysis ofßPatients Treated withßCanagliflozin4.3.2 Renoprotective Aspects ofßSGLT2 Inhibitors; 4.3.3 Renal Outcome Studies withßSGLT2 Inhibitors; 4.4 SGLT2 Inhibitors inßOlder Patients withßType 2 Diabetes; 4.4.1 Dapagliflozin inßOlder Patients withßType 2 Diabetes; 4.4.2 Canagliflozin inßOlder Patients withßType 2 Diabetes; 4.5 SGLT2 Inhibitors inßType 1 Diabetes; 4.5.1 Empagliflozin inßType 1 Diabetes; 4.5.2 Dapaglifozin inßType 1 Diabetes; 4.5.3 Sotagliflozin inßType 1 Diabetes; 4.5.4 Future Prospects inßType 1 Diabetes; References.
000778009 506__ $$aAccess limited to authorized users.
000778009 588__ $$aDescription based on print  version record.
000778009 650_0 $$aNon-insulin-dependent diabetes$$xChemotherapy.
000778009 7001_ $$aMcKay, Gerard A.
000778009 77608 $$iPrint version:$$aFisher, Miles.$$tEssentials of SGLT2 Inhibitors in Diabetes.$$dCham : Springer International Publishing, ©2016$$z9783319432946
000778009 852__ $$bebk
000778009 85640 $$3SpringerLink$$uhttps://univsouthin.idm.oclc.org/login?url=http://link.springer.com/10.1007/978-3-319-43296-0$$zOnline Access$$91397441.1
000778009 909CO $$ooai:library.usi.edu:778009$$pGLOBAL_SET
000778009 980__ $$aEBOOK
000778009 980__ $$aBIB
000778009 982__ $$aEbook
000778009 983__ $$aOnline
000778009 994__ $$a92$$bISE